Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has scheduled a conference call for 9th November 2020 at 4:30 PM Eastern Time to announce its 3Q20 financial results.
The conference call will also be webcast live under the investor relations section of the website www.arenapharm.com
Earnings Expectation
Arena Pharmaceuticals, Inc. is reporting third quarter financial results on Monday 9th November 2020, after market close.
According to analysts surveyed by Thomson Reuters, ARNA is expected to report 3Q20 loss of $ 1.87 per share from revenue of $ 1.23 million.
For the full year, analysts anticipate top line of $ 2.73 million, while looking forward to loss of $ 7.61 per share bottom line.
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include ralinepag (APD811), which is in Phase III trial to treat pulmonary arterial hypertension; etrasimod (APD334) for ulcerative colitis, and Crohns disease, as well as for atopic dermatitis and other indications; and Olorinab (APD371), which is in Phase II trial for the treatment of gastrointestinal pain. It is also developing APD418, a calcium-independent myofilament derepressor for the treatment of decompensated heart failure.
